Detailed Information

Cited 18 time in webofscience Cited 7 time in scopus
Metadata Downloads

A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Optionsopen access

Authors
Park, Jun YongHeo, JeongLee, Tae JinYim, Hyung JoonYeon, Jong EunLim, Young-SukSeo, Min JeongAhn, Sang HoonLee, Myung Seok
Issue Date
11-Mar-2013
Publisher
PUBLIC LIBRARY SCIENCE
Citation
PLOS ONE, v.8, no.3
Indexed
SCIE
SCOPUS
Journal Title
PLOS ONE
Volume
8
Number
3
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/10896
DOI
10.1371/journal.pone.0057900
ISSN
1932-6203
Abstract
Background: Prescribers, payors and healthcare decision-makers are increasingly examining the value of treatments. This study aims at analyzing economic value of chronic hepatitis B (CHB) treatment options, which are available in Korea. Methods: CHB infection was simulated using a health-state transition model with disease states defined as mild disease (Ishak F0/F1), fibrosis (F2/F3/F4), advanced fibrosis/cirrhosis (> F4), and complicated disease states (decompensated cirrhosis, hepatocellular carcinoma, liver transplant and death) based on available natural history data. The value of treatment-specific attributes on disease progression/regression was estimated based on published data in terms of events and costs avoided. 5-year treatment duration was assumed except for treatment initiation. Primary model output is the estimated cost savings of entecavir per patient per day of treatment versus the comparator in question for a given CHB patient. Results: The simulation of treating with entecavir versus no treatment predicted improved clinical outcomes for entecavir-treatment patients. In the long term, these clinical benefits translate into cost savings of $3.10 per day of treatment. In naive patient treatment, daily cost savings of using entecavir versus lamivudine or telbivudine was estimated at $2.89 and $1.72, respectively. In the case of suboptimal responders who pre-treated with lamivudine, daily cost saving for patients switching to entecavir was $1.38 per day of treatment compared to patients maintaining on lamivudine. Conclusions: Entecavir exhibits characteristics of a favourable CHB treatment, which directly translates into economic and therapeutic value as opposed to either no treatment or alternative strategies.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yeon, Jong Eun photo

Yeon, Jong Eun
Guro Hospital (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE